BioStock Studio: Gabather gives clinical trial update
Gabather’s top candidate GT-002 for treating psychiatric or mood disorders like depression, anxiety, and schizophrenia is currently in the early stages of clinical development. The company is planning a key target engagement study in healthy volunteers aimed at showing how GT-002 modulates brain activity at both the functional and regional levels of the brain. The company's CEO Michael-Robin Witt joined BioStock via link to tell us more about GT-002 and give us an update on the ongoing clinical trial.
Watch the interview with Gabather's CEO Michael-Robin Witt at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/